Cowen & Co. analyst Boris Peaker came out with some commentary on Idera Pharmaceuticals Inc (NASDAQ:IDRA), following the company’s new-found research alliance with MD Anderson to test …
Idera Pharmaceuticals Inc (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, announced that …
Idera Pharmaceuticals Inc (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, announced the …
Idera Pharmaceuticals Inc (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for oncology and rare diseases, …
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for oncology and rare diseases, today …
Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for oncology and rare diseases, reported …
Idera Pharmaceuticals, Inc. (Nasdaq:IDRA) (“Idera” or the “Company”) today announced the pricing of an underwritten public offering of 20,000,000 shares of common stock …
Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing immune-modulating and gene silencing therapies for cancer and rare diseases, today announced the appointments …
Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced …
Cowen analyst Boris Peaker maintained an Outperform rating on Idera Pharmaceuticals (NASDAQ:IDRA), as the company announced that data for its lead product candidate IMO-8400 …
